Enhancing efferocytosis or cholesterol efflux—such as blocking the CD47-SIRPα axis with anti-CD47 antibodies or SHP1 inhibitors—attenuates atherosclerosis [9,10,15,35,36]. Here, CD47 is linked to atherosclerosis.